Core Viewpoint - Driven Brands Holdings Inc. (DRVN) is expected to report a year-over-year increase in earnings despite lower revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate for quarterly earnings is $0.32 per share, reflecting a year-over-year increase of +6.7% [3]. - Revenues are projected to be $459.43 million, which is a decrease of 18.6% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - The Most Accurate Estimate for Driven Brands Holdings is lower than the Zacks Consensus Estimate, leading to an Earnings ESP of -31.25% [11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with positive readings being more predictive of earnings beats [8][9]. - Driven Brands Holdings currently has a Zacks Rank of 4, which complicates the prediction of an earnings beat [11]. Historical Performance - In the last reported quarter, Driven Brands Holdings exceeded the expected earnings of $0.29 per share by delivering $0.34, resulting in a surprise of +17.24% [12]. - The company has beaten consensus EPS estimates in all of the last four quarters [13]. Conclusion - Driven Brands Holdings does not appear to be a strong candidate for an earnings beat based on current estimates and rankings, but other factors should also be considered for investment decisions [16].

Core Viewpoint - Kinetik Holdings Inc. (KNTK) is anticipated to report a significant year-over-year increase in earnings driven by higher revenues, with the actual results being crucial for its near-term stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected to show quarterly earnings of $0.15 per share, reflecting a year-over-year increase of 1400% [3]. - Revenues are projected to reach $515.13 million, which is a 33.6% increase compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 48.49% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Kinetik Holdings is the same as the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - A positive Earnings ESP is generally a strong indicator of an earnings beat, especially when combined with a favorable Zacks Rank [10]. - Kinetik Holdings currently holds a Zacks Rank of 5, which complicates the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Kinetik Holdings met the expected earnings of $0.23 per share, resulting in no surprise [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Conclusion - Kinetik Holdings does not appear to be a strong candidate for an earnings beat, and investors should consider additional factors when making investment decisions ahead of the earnings release [17].

Core Viewpoint - Sarepta Therapeutics (SRPT) is anticipated to report a year-over-year decline in earnings due to lower revenues, with a consensus outlook indicating a quarterly loss of $0.71 per share, reflecting a -147.3% change from the previous year, and revenues expected to be $408.53 million, down 38% from the year-ago quarter [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for February 25, and the stock may rise if the reported numbers exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised down by 45.87% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP (Expected Surprise Prediction) model suggests that the Most Accurate Estimate for Sarepta is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +2.11% [12]. - The stock currently holds a Zacks Rank of 3, indicating a hold position, which suggests a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Sarepta was expected to post earnings of $0.01 per share but instead reported a loss of -$0.13, resulting in a surprise of -1,400.00% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Industry Context - In the broader context of the Zacks Medical - Biomedical and Genetics industry, Cytokinetics (CYTK) is also expected to report a loss of $1.48 per share, reflecting a year-over-year change of -17.5%, with revenues expected to be $3.89 million, down 77% from the previous year [18][19].

Core Viewpoint - Starwood Property Trust (STWD) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending December 2025, with actual results being crucial for stock price movement [1][3]. Earnings Expectations - The consensus estimate for quarterly earnings is $0.41 per share, reflecting a year-over-year decrease of 14.6%, while revenues are projected to reach $479.3 million, a 5.5% increase from the previous year [3]. - The stock may experience upward movement if earnings exceed expectations, whereas a miss could lead to a decline [2]. Estimate Revisions - Over the past 30 days, the consensus EPS estimate has been revised down by 2.44%, indicating a reassessment by analysts regarding the company's earnings outlook [4]. - The Most Accurate Estimate for Starwood Property Trust is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.64%, suggesting a bearish sentiment among analysts [12]. Historical Performance - In the last reported quarter, Starwood Property Trust was expected to earn $0.45 per share but only achieved $0.40, resulting in a surprise of -11.11% [13]. - Over the last four quarters, the company has beaten consensus EPS estimates twice [14]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a favorable Zacks Rank [10]. - Currently, Starwood Property Trust holds a Zacks Rank of 4, which complicates the prediction of an earnings beat [12]. Conclusion - Starwood Property Trust does not appear to be a strong candidate for an earnings beat, and investors should consider additional factors when making decisions regarding the stock ahead of the earnings release [17].

Core Viewpoint - Acadia Pharmaceuticals (ACAD) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending December 2025, with the consensus outlook indicating a significant impact on its stock price based on actual results compared to estimates [1][2]. Earnings Expectations - The upcoming earnings report is expected to show earnings of $0.12 per share, reflecting a year-over-year decrease of 29.4%, while revenues are projected to be $292.58 million, representing a 12.7% increase from the previous year [3]. - The consensus EPS estimate has been revised 3.23% higher in the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4]. Earnings Surprise Prediction - The Zacks Earnings ESP (Expected Surprise Prediction) model suggests that a positive Earnings ESP reading of +14.92% indicates a likelihood of Acadia beating the consensus EPS estimate, although the company currently holds a Zacks Rank of 3 [12]. - Historical performance shows that Acadia has beaten consensus EPS estimates three out of the last four quarters, with a notable surprise of +85.71% in the last reported quarter [13][14]. Industry Context - Day One Biopharmaceuticals, another player in the same industry, is expected to report a loss of $0.17 per share for the same quarter, which is a year-over-year increase of 75.4%, with revenues expected to rise by 65.1% to $48.22 million [18][19]. - Despite a significant upward revision of 53.1% in the consensus EPS estimate for Day One Biopharmaceuticals over the last 30 days, it currently has a negative Earnings ESP of -29.00%, complicating predictions for beating the consensus EPS estimate [19][20].

Core Viewpoint - APA is expected to report a year-over-year decline in earnings and revenues for the quarter ended December 2025, which could significantly impact its stock price depending on how actual results compare to estimates [1][3]. Earnings Expectations - The consensus estimate for APA's quarterly earnings is $0.62 per share, reflecting a year-over-year decrease of 21.5% [3]. - Revenues are projected to be $1.92 billion, down 23.2% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 5.13% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for APA is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.28% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a potential earnings beat, especially when combined with a strong Zacks Rank [10]. - However, APA currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat despite the positive Earnings ESP [12]. Historical Performance - In the last reported quarter, APA exceeded the consensus EPS estimate of $0.74 by delivering earnings of $0.93, resulting in a surprise of +25.68% [13]. - Over the past four quarters, APA has beaten consensus EPS estimates three times [14]. Industry Comparison - Matador Resources, another company in the oil and gas sector, is expected to report earnings of $0.79 per share for the same quarter, indicating a year-over-year decline of 56.8% [18]. - Matador's revenues are expected to be $830.78 million, down 14.4% from the previous year, with a Zacks Rank of 4 and an Earnings ESP of -5.58% [19][20].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for AMC Entertainment despite lower revenues, with a focus on how actual results will compare to estimates [1][2]. Earnings Expectations - AMC is expected to report a quarterly loss of $0.16 per share, reflecting an 11.1% year-over-year change, while revenues are projected to be $1.28 billion, down 2.4% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 10% lower in the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][12]. Earnings Surprise Prediction - The Most Accurate Estimate for AMC is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -12.17%, which complicates the prediction of an earnings beat [12]. - A positive Earnings ESP is generally a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. Historical Performance - In the last reported quarter, AMC was expected to post a loss of $0.19 per share but actually reported a loss of $0.21, resulting in a surprise of -10.53% [13]. - Over the past four quarters, AMC has beaten consensus EPS estimates twice [14]. Conclusion - AMC Entertainment does not appear to be a strong candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of its earnings release [17].

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Carter's (CRI) despite an increase in revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Carter's is expected to report quarterly earnings of $1.70 per share, reflecting a year-over-year decrease of 28.9%, while revenues are projected to be $916.4 million, an increase of 6.6% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.96% higher in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Carter's is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.48%, indicating bearish sentiment among analysts [12]. Historical Performance - In the last reported quarter, Carter's had an expected EPS of $0.78 but reported $0.74, resulting in a surprise of -5.13%. Over the last four quarters, the company has beaten consensus EPS estimates twice [13][14]. Investment Considerations - Despite a Zacks Rank of 1 (Strong Buy), the negative Earnings ESP reading complicates predictions of an earnings beat for Carter's [12]. Investors should consider other factors beyond earnings results when evaluating the stock [15][17].

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Carlyle Secured Lending, Inc. (CGBD) despite higher revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected to show quarterly earnings of $0.38 per share, reflecting a year-over-year decrease of 19.2%, while revenues are projected to be $45.58 million, an increase of 16.2% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial projections [4]. Earnings Surprise Prediction - The Most Accurate Estimate for Carlyle Secured Lending is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.60%, suggesting a bearish outlook from analysts [11]. Historical Performance - In the last reported quarter, Carlyle Secured Lending was expected to post earnings of $0.39 per share but delivered $0.38, resulting in a surprise of -2.56%. Over the last four quarters, the company has only beaten consensus EPS estimates once [12][13]. Investment Considerations - While the company does not appear to be a strong candidate for an earnings beat, investors should consider other factors influencing stock performance beyond earnings results [16].

Core Viewpoint - Cytokinetics (CYTK) is anticipated to report a year-over-year decline in earnings due to lower revenues, with a consensus outlook indicating a quarterly loss of $1.48 per share, representing a 17.5% decrease from the previous year, and revenues expected to be $3.89 million, down 77% from the same quarter last year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for February 24, and the stock may rise if the reported numbers exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 1.25% lower in the last 30 days, reflecting a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Cytokinetics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.95%, suggesting a bearish outlook from analysts [11]. - The stock currently holds a Zacks Rank of 3, making it challenging to predict a beat on the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Cytokinetics was expected to post a loss of $1.59 per share but actually reported a loss of -$1.54, resulting in a positive surprise of +3.14% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [13]. Conclusion - While Cytokinetics does not appear to be a strong candidate for an earnings beat, investors should consider other factors when making decisions regarding the stock ahead of the earnings release [16].